Cargando…
Corrections to “Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer”
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340185/ https://www.ncbi.nlm.nih.gov/pubmed/30624616 http://dx.doi.org/10.1093/annonc/mdy529 |
| _version_ | 1783555002658193408 |
|---|---|
| author | Baselga, J. Manikhas, A. Cortés, J. Llombart, A. Roman, L. Semiglazov, V.F. Byakhov, M. Lokanatha, D. Forenza, S. Goldfarb, R.H. Matera, J. Azarnia, N. Hudis, C.A. Rozencweig, M. |
| author_facet | Baselga, J. Manikhas, A. Cortés, J. Llombart, A. Roman, L. Semiglazov, V.F. Byakhov, M. Lokanatha, D. Forenza, S. Goldfarb, R.H. Matera, J. Azarnia, N. Hudis, C.A. Rozencweig, M. |
| author_sort | Baselga, J. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7340185 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-73401852020-07-14 Corrections to “Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer” Baselga, J. Manikhas, A. Cortés, J. Llombart, A. Roman, L. Semiglazov, V.F. Byakhov, M. Lokanatha, D. Forenza, S. Goldfarb, R.H. Matera, J. Azarnia, N. Hudis, C.A. Rozencweig, M. Ann Oncol Corrigenda Oxford University Press 2019-06 2019-12-04 /pmc/articles/PMC7340185/ /pubmed/30624616 http://dx.doi.org/10.1093/annonc/mdy529 Text en © 2019 THE AUTHORS http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Corrigenda Baselga, J. Manikhas, A. Cortés, J. Llombart, A. Roman, L. Semiglazov, V.F. Byakhov, M. Lokanatha, D. Forenza, S. Goldfarb, R.H. Matera, J. Azarnia, N. Hudis, C.A. Rozencweig, M. Corrections to “Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer” |
| title | Corrections to “Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer” |
| title_full | Corrections to “Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer” |
| title_fullStr | Corrections to “Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer” |
| title_full_unstemmed | Corrections to “Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer” |
| title_short | Corrections to “Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer” |
| title_sort | corrections to “phase iii trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in her2-positive metastatic breast cancer” |
| topic | Corrigenda |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340185/ https://www.ncbi.nlm.nih.gov/pubmed/30624616 http://dx.doi.org/10.1093/annonc/mdy529 |
| work_keys_str_mv | AT baselgaj correctionstophaseiiitrialofnonpegylatedliposomaldoxorubicinincombinationwithtrastuzumabandpaclitaxelinher2positivemetastaticbreastcancer AT manikhasa correctionstophaseiiitrialofnonpegylatedliposomaldoxorubicinincombinationwithtrastuzumabandpaclitaxelinher2positivemetastaticbreastcancer AT cortesj correctionstophaseiiitrialofnonpegylatedliposomaldoxorubicinincombinationwithtrastuzumabandpaclitaxelinher2positivemetastaticbreastcancer AT llombarta correctionstophaseiiitrialofnonpegylatedliposomaldoxorubicinincombinationwithtrastuzumabandpaclitaxelinher2positivemetastaticbreastcancer AT romanl correctionstophaseiiitrialofnonpegylatedliposomaldoxorubicinincombinationwithtrastuzumabandpaclitaxelinher2positivemetastaticbreastcancer AT semiglazovvf correctionstophaseiiitrialofnonpegylatedliposomaldoxorubicinincombinationwithtrastuzumabandpaclitaxelinher2positivemetastaticbreastcancer AT byakhovm correctionstophaseiiitrialofnonpegylatedliposomaldoxorubicinincombinationwithtrastuzumabandpaclitaxelinher2positivemetastaticbreastcancer AT lokanathad correctionstophaseiiitrialofnonpegylatedliposomaldoxorubicinincombinationwithtrastuzumabandpaclitaxelinher2positivemetastaticbreastcancer AT forenzas correctionstophaseiiitrialofnonpegylatedliposomaldoxorubicinincombinationwithtrastuzumabandpaclitaxelinher2positivemetastaticbreastcancer AT goldfarbrh correctionstophaseiiitrialofnonpegylatedliposomaldoxorubicinincombinationwithtrastuzumabandpaclitaxelinher2positivemetastaticbreastcancer AT materaj correctionstophaseiiitrialofnonpegylatedliposomaldoxorubicinincombinationwithtrastuzumabandpaclitaxelinher2positivemetastaticbreastcancer AT azarnian correctionstophaseiiitrialofnonpegylatedliposomaldoxorubicinincombinationwithtrastuzumabandpaclitaxelinher2positivemetastaticbreastcancer AT hudisca correctionstophaseiiitrialofnonpegylatedliposomaldoxorubicinincombinationwithtrastuzumabandpaclitaxelinher2positivemetastaticbreastcancer AT rozencweigm correctionstophaseiiitrialofnonpegylatedliposomaldoxorubicinincombinationwithtrastuzumabandpaclitaxelinher2positivemetastaticbreastcancer |